TLIS Stock Analysis
TL
Uncovered
Talis Biomedical Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Redwood City, California and currently employs 242 full-time employees. The company went IPO on 2021-02-12. The firm is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. The company is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). The company is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.